These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37546311)

  • 1. To PCR or not? The impact of shifting policy from PCR to rapid antigen tests to diagnose COVID-19 during the omicron epidemic: a nationwide surveillance study.
    Chi H; Chiu NC; Chen CC; Weng SL; Lien CH; Lin CH; Hu YF; Lei WT; Tai YL; Lin LY; Liu LY; Lin CY
    Front Public Health; 2023; 11():1148637. PubMed ID: 37546311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Sharma P; Berhane S; van Wyk SS; Nyaaba N; Domen J; Taylor M; Cunningham J; Davenport C; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Van den Bruel A; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013705. PubMed ID: 35866452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal screening for SARS-CoV-2 infection: a rapid review.
    Viswanathan M; Kahwati L; Jahn B; Giger K; Dobrescu AI; Hill C; Klerings I; Meixner J; Persad E; Teufer B; Gartlehner G
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013718. PubMed ID: 33502003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T; Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Leeflang MM; Spijker R; Hooft L; Emperador D; Domen J; Tans A; Janssens S; Wickramasinghe D; Lannoy V; Horn SRA; Van den Bruel A;
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013665. PubMed ID: 35593186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the Rapid Antigen Detection Kit with the Polymerase Chain Reaction for Detection of SARS-CoV-2 in Respiratory Samples].
    Erman Daloğlu A; Er H; Sepin Özen N; Çekin Y
    Mikrobiyol Bul; 2022 Apr; 56(2):263-273. PubMed ID: 35477229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Nasopharyngeal and Saliva Swab Nucleic Acid Amplification and Rapid Antigen Testing To Detect Omicron SARS-CoV-2 Variant of Concern: a Prospective Clinical Trial (OMICRON).
    Kritikos A; Caruana G; Lazor-Blanchet C; Currat M; Chiche JD; Vollenweider P; Bart PA; Opota O; Greub G
    Microbiol Spectr; 2022 Dec; 10(6):e0392322. PubMed ID: 36346225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of RT-PCR and antigen-based rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 detection: performance, variant specificity, and clinical implications.
    Aboagye FT; Annison L; Hackman HK; Acquah ME; Ashong Y; Owusu-Frimpong I; Egyam BC; Annison S; Osei-Adjei G; Antwi-Baffour S
    Microbiol Spectr; 2024 Jun; 12(6):e0007324. PubMed ID: 38683014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass Screening of SARS-CoV-2 With Rapid Antigen Tests in a Receding Omicron Wave: Population-Based Survey for Epidemiologic Evaluation.
    Kwan TH; Wong NS; Chan CP; Yeoh EK; Wong SY; Lee SS
    JMIR Public Health Surveill; 2022 Nov; 8(11):e40175. PubMed ID: 36240027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.
    Marquez C; Kerkhoff AD; Schrom J; Rojas S; Black D; Mitchell A; Wang CY; Pilarowski G; Ribeiro S; Jones D; Payan J; Manganelli S; Rojas S; Lemus J; Jain V; Chamie G; Tulier-Laiwa V; Petersen M; DeRisi J; Havlir DV
    JAMA Netw Open; 2022 Oct; 5(10):e2235844. PubMed ID: 36215069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence Estimates: Findings From a US National Cohort, February 2022.
    Qasmieh SA; Robertson MM; Rane MS; Shen Y; Zimba R; Picchio CA; Parcesepe AM; Chang M; Kulkarni SG; Grov C; Nash D
    JMIR Public Health Surveill; 2022 Dec; 8(12):e38196. PubMed ID: 36240020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policy choices for Shanghai responding to challenges of Omicron.
    Qian Y; Cao S; Zhao L; Yan Y; Huang J
    Front Public Health; 2022; 10():927387. PubMed ID: 36016887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 rapid antigen testing positive rate in community testing stations as an indicator for COVID-19 epidemic trend, Taipei, Taiwan, May to August 2021.
    Niu KY; Cheng YC; Chan CW; Chaou CH; Yen CC; Fang CT
    J Formos Med Assoc; 2024 Jun; 123(6):716-719. PubMed ID: 38044208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.